DURECT announces positive data from phase 2a clinical trial of DUR-928 in AH patients
DURECT announced it has completed the Phase 2a clinical trial of its lead product candidate, DUR-928, in patients with alcoholic hepatitis. The final enrollment for the trial consists of 12 severe patients (MELD 21-30) and 7 moderate patients (MELD 11-20) for a total of 19 AH patients. September 17, 2019